Natural products as inhibitors of epidermal growth factor receptor

Forum on Immunopathological Diseases and Therapeutics

Volumn 2, Issue 4, 2011, Pages 281-301

  Efferth, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cancer; Pharmacognosy; Phytochemicals; Small molecules; Traditional Chinese medicine; Tyrosine kinase activity

Indexed keywords

CARAGANA JUBATA EXTRACT; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIGALLOCATECHIN GALLATE; ERBSTATIN; ERBSTATIN DERIVATIVE; ERLOTINIB; FISETIN; GEFITINIB; GEMCITABINE; GENISTEIN; GRAPE SEED EXTRACT; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAVENDUSTIN A; MD 831; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NATURAL PRODUCT; PLANT EXTRACT; PLANT MEDICINAL PRODUCT; PROCYANIDIN DERIVATIVE; PROTEIN KINASE B; TANNIN; THEAFLAVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CARAGANA; CARAGANA JUBATA; COLON CANCER; DRUG ISOLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SYNTHESIS; FOOD COMPOSITION; FOOD INTAKE; HUMAN; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MARINE SPECIES; MICROORGANISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

ANIMALIA;

EID: 84860774719     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.2012004386     Document Type: Review

References (77)

1. Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res. 2006;12(24):7242-51. (Pubitemid 46095395)
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37. (Pubitemid 33674041)
3. Wang K, Yamamoto H, Chin JR, Werb Z, Vu TH. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem. 2004;279(51):53848-56. (Pubitemid 40051894)
4. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002;29(1 Suppl 4):27-36. (Pubitemid 34226516)
5. Ethier SP. Signal transduction pathways: the molecular basis for targeted therapies. Semin Radiat Oncol. 2002;12(3 Suppl 2):3-10. (Pubitemid 34920086)
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. (Pubitemid 17231334)
7. Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev Anticancer Ther. 2007;7(3):317-29. (Pubitemid 46488337)
8. Efferth T, Volm M. Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect Prev. 1992;16(4):237-43.
9. Efferth T, Volm M. Antibody-directed therapy of multidrug-resistant tumor cells. Med Oncol Tumor Pharmacother. 1992;9(1):11-19.
10. Halatsch ME, Gehrke EE, Vougioukas VI, Bötefür IC, A-Borhani F, Efferth T, Gebhart E, Domhof S, Schmidt U, Buchfelder MF. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J Neurosurg. 2004;100(3):523-33. (Pubitemid 38269082)
11. Perea S, Hidalgo M. Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clin Lung Cancer. 2004;6 Suppl 1:S30-34.
12. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Janne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462(7276):1070-74.
13. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461-77. (Pubitemid 46595760)
14. Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. Int J Cancer. 1998;78(6):775-82. (Pubitemid 28530402)
15. Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer. 2009;115(10):2165-76.
16. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006;66(21):10553-59. (Pubitemid 44799778)
17. Oh HY, Leem J, Yoon SJ, Yoon S, Hong SJ. Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochem Biophys Res Commun. 2010;393(2):319-24.
18. Yan GR, Xiao CL, He GW, Yin XF, Chen NP, Cao Y, He QY. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics. 2010;10(5):976-86.
19. Croisy-Delcey M, Croisy A, Mousset S, Letourneur M, Bisagni E, Jacquemin-Sablon A, Pierre J. Genistein analogues: effects on epidermal growth factor receptor tyrosine kinase and on stress-activated pathways. Biomed Pharmacother. 1997;51(6-7):286-94. (Pubitemid 27296841)
20. Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evans W. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor. Clin Cancer Res. 1998;4(5):1125-34. (Pubitemid 28213322)
21. Brown NM, Wang J, Cotroneo MS, Zhao YX, Lamartiniere CA. Prepubertal genistein treatment modulates TGF-alpha, EGF and EGF-receptor mRNAs and proteins in the rat mammary gland. Mol Cell Endocrinol. 1998;144(1-2):149-65. (Pubitemid 28491310)
22. Cotroneo MS, Fritz WA, Lamartiniere CA. Dynamic profiling of estrogen receptor and epidermal growth factor signaling in the uteri of genistein- and estrogen-treated rats. Food Chem Toxicol. 2005;43(5):637-45. (Pubitemid 40381165)
23. Jiang L, Jiang LS, Yan LN, Li FY, Wang W, Cheng NS, Wen TF. Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats. J Surg Res. 2010;162(1):59-67.
24. Nakamura H, Wang Y, Kurita T, Adomat H, Cunha GR, Wang Y. Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS One. 2011;6(5):e20034.
25. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3- gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004;279(13):12755-62. (Pubitemid 38445847)
26. Mizuno H, Cho YY, Zhu F, Ma WY, Bode AM, Yang CS, Ho CT, Dong Z. Theaflavin-3, 3' digallate induces epidermal growth factor receptor downregulation. Mol Carcinog. 2006;45(3):204-12. (Pubitemid 43358153)
27. Pan MH, Lin CC, Lin JK, Chen WJ. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. J Agric Food Chem. 2007;55(13):5030-37.
28. Tyagi A, Agarwal R, Agarwal C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene. 2003;22(9):1302-16. (Pubitemid 36384591)
29. Suh Y, Afaq F, Johnson JJ, Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/EGFR/NF-kappaB- signaling pathways. Carcinogenesis. 2009;30(2):300-7.
30. Zhu L, Xu X. Selective separation of active inhibitors of epidermal growth factor receptor from Caragana jubata by molecularly imprinted solid-phase extraction. J Chromatogr A. 2003;991(2):151-58. (Pubitemid 36349644)
31. Zhu L, Chen L, Xu X. Application of a molecularly imprinted polymer for the effective recognition of different anti-epidermal growth factor receptor inhibitors. Anal Chem. 2003;75(23):6381-87. (Pubitemid 37493890)
32. Chen X, Beutler JA, McCloud TG, Loehfelm A, Yang L, Dong HF, Chertov OY, Salcedo R, Oppenheim JJ, Howard OM. Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity. Clin Cancer Res. 2003;9(8):3115-23. (Pubitemid 36993274)
33. Shen SC, Ko CH, Hsu KC, Chen YC. 3-OH flavone inhibition of epidermal growth factor induced proliferaton through blocking prostaglandin E2 production. Int J Cancer. 2004;108(4):502-10. (Pubitemid 38036649)
34. Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, Lin LP, Ding J. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochim Biophys Acta. 2004;1673(3):186-93. (Pubitemid 38981772)
35. Zhang YX, Chen Y, Guo XN, Zhang XW, Zhao WM, Zhong L, Zhou J, Xi Y, Lin LP, Ding J. 11,11'-dideoxy-verticillin: a natural compound possessing growth factor receptor tyrosine kinase-inhibitory effect with anti-tumor activity. Anticancer Drugs. 2005;16(5):515-24. (Pubitemid 40685736)
36. Huang WC, Hsu RM, Chi LM, Leu YL, Chang YS, Yu JS. Selective downregulation of EGF receptor and downstream MAPK pathway in human cancer cell lines by active components partially purified from the seeds of Livistona chinensis R. Brown. Cancer Lett. 2007;248(1):137-46.
37. Wang T, Wang Y, Yamashita H. Evodiamine inhibits adipogenesis via the EGFR-PKCalpha ERK signaling pathway. FEBS Lett. 2009;583(22):3655-59.
38. Way TD, Lee JC, Kuo DH, Fan LL, Huang CH, Lin HY, Shieh PC, Kuo PT, Liao CF, Liu H, Kao JY. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells. J Agric Food Chem. 2010;58(6):3356-65.
39. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010;16(9):2571-79.
40. Singh F, Gao D, Lebwohl MG, Wei H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett. 2003;200(2):115-21. (Pubitemid 38366091)
41. Kang N, Zhang JH, Qiu F, Tashiro SI, Onodera S, Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett. 2010;294(2):147-58.
42. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, Shibuya M, Yamori T, Nakaya K. Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res. 2002;93(8):944-51. (Pubitemid 35012257)
43. Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Beta- hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;109(1):107-14.
44. Konkimalla VB, Efferth T. Anti-cancer natural product library from traditional Chinese medicine. Comb Chem High Throughput Screen. 2008;11(1):7-15.
45. Konkimalla VB, Efferth T. Inhibition of epidermal growth factor receptor overexpressing cancer cells by the aphorphinetype isoquinoline alkaloid, dicentrine. Biochem Pharmacol. 2010a;79(8):1092-99.
46. Huang RL, Chen CC, Huang YL, Ou JC, Hu CP, Chen CF, Chang C. Anti-tumor effects of d-dicentrine from the root of Lindera megaphylla. Planta Med. 1998;64(3):212-15.
47. Voigt W, Vanhoefer U, Yin MB, Minderman H, Schmoll HJ, Rustum YM. Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines. Anticancer Res 1997;17:3707-11. (Pubitemid 27522350)
48. Kancherla RR, Nair JS, Ahmed T, Durrani H, Seiter K, Mannancheril A, Tse-Dinh YC. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response. Cancer 2001;91:463-71. (Pubitemid 32105690)
49. Konkimalla VB, Efferth T. Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate. Biochem Pharmacol. 2010;80(1):39-49.
50. Skarlos DV, Bai M, Goussia A, Samantas E, Galani E, Tsavdaridis D, Karina M, Papakostas P, Konstantara A, Fountzilas G. Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res. 2007;27:2973-83. (Pubitemid 47228031)
51. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64(2):382-94. (Pubitemid 36910002)
52. Efferth T, Ramirez T, Gebhart E, Halatsch ME. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol. 2004;67(9):1689-700. (Pubitemid 38479847)
53. Konkimalla VB, McCubrey JA, Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for artesunate's activity in cancer cells. Curr Cancer Drug Targets.2009;9(1):72-80.
54. Wheeler LA, Sachs G, De Vries G, Goodrum D, Woldemussie E, Muallem S. Manoalide, a natural sesterterpenoid that inhibits calcium channels. J Biol Chem. 1987;262(14):6531-38. (Pubitemid 17104139)
55. Lee RH, Slate DL, Moretti R, Alvi KA, Crews P. Marine sponge polyketide inhibitors of protein tyrosine kinase. Biochem Biophys Res Commun. 1992;184(2):765-72.
56. Xie Y, Liu L, Huang X, Guo Y, Lou L. Scalaradial inhibition of epidermal growth factor receptor-mediated Akt phosphorylation is independent of secretory phospholipase A2. J Pharmacol Exp Ther. 2005;314(3):1210-17. (Pubitemid 41205986)
57. Xie Y, Yu Z, Liu L, Guo Y, Lou L. Biphasic regulation of extracellular signal-regulated kinases by scalaradial, a secretory phospholipase A(2) inhibitor. Cancer Biol Ther. 2006;5(8):988-92.
58. Nakamura H, Iitaka Y, Imoto M, Isshiki K, Naganawa H, Takeuchi T, Umezawa H. The structure of an epidermal growth factor-receptor kinase inhibitor, erbstatin. J Antibiot (Tokyo). 1986 Feb;39(2):314-15. Erratum in J Antibiot (Tokyo) 1986;39(8):following 1191.
59. Umezawa H, Imoto M, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada M, Takeuchi T. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiot (Tokyo). 1986;39(1):170-73. (Pubitemid 16174654)
60. Imoto M, Umezawa K, Isshiki K, Kunimoto S, Sawa T, Takeuchi T, Umezawa H. Kinetic studies of tyrosine kinase inhibition by erbstatin. J Antibiot (Tokyo). 1987;40(10):1471-73. (Pubitemid 17146792)
61. Umezawa K, Imoto M. Use of erbstatin as protein-tyrosine kinase inhibitor. Methods Enzymol. 1991;201:379-85.
62. Imoto M, Umezawa K, Sawa T, Takeuchi T, Umezawa H. In situ inhibition of tyrosine protein kinase by erbstatin. Biochem Int. 1987;15(5):989-95. (Pubitemid 18078425)
63. Toi M, Mukaida H, Wada T, Hirabayashi N, Toge T, Hori T, Umezawa K. Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic nude mice. Eur J Cancer. 1990;26(6):722-24. (Pubitemid 20275109)
64. Takekura N, Yasui W, Kyo E, Yoshida K, Kameda T, Kitadai Y, Abe K, Umezawa K, Tahara E. Effects of tyrosine kinase inhibitor, erbstatin, on cell growth and growth-factor/receptor gene expression in human gastric carcinoma cells. Int J Cancer. 1991;47(6):938-42.
65. Markovits J, Larsen AK, Ségal-Bendirdjian E, Fossé P, Saucier JM, Gazit A, Levitzki A, Umezawa K, Jacquemin-Sablon A. Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem Pharmacol. 1994;48(3):549-60. (Pubitemid 24257018)
66. McIntyre BS, Sylvester PW. Genistein and erbstatin inhibition of normal mammary epithelial cell proliferation is associated with EGF-receptor down-regulation. Cell Prolif. 1998;31(1):35-46. (Pubitemid 28274194)
67. Bishop WR, Petrin J, Wang L, Ramesh U, Doll RJ. Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol. 1990;40(9):2129-35. (Pubitemid 20346466)
68. Umezawa K, Hori T, Tajima H, Imoto M, Isshiki K, Takeuchi T. Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett. 1990;260(2):198-200. (Pubitemid 20042366)
69. Umezawa K, Sugata D, Yamashita K, Johtoh N, Shibuya M. Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors in NIH3T3 cells. FEBS Lett. 1992;314(3):289-92. (Pubitemid 23005675)
70. Hsu CY, Jacoski MV, Maguire MP, Spada AP, Zilberstein A. Inhibition kinetics and selectivity of the tyrosine kinase inhibitor erbstatin and a pyridone-based analogue. Biochem Pharmacol. 1992;43(11):2471-77.
71. Treuner M, Böhmer FD, Schulze W, Petuchov SP, Grosse R. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition. Biochem Int. 1992;26(4):617-25.
72. Stanwell C, Burke TR Jr, Yuspa SH. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Cancer Res. 1995;55(21):4950-56.
73. Onoda T, Iinuma H, Sasaki Y, Hamada M, Isshiki K, Naganawa H, Takeuchi T, Tatsuta K, Umezawa K. Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus. J Nat Prod. 1989;52(6):1252-57. (Pubitemid 20101774)
74. Smyth MS, Stefanova I, Hartmann F, Horak ID, Osherov N, Levitzki A, Burke TR Jr. Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem. 1993;36(20):3010-14. (Pubitemid 23315406)
75. Posner I, Engel M, Gazit A, Levitzki A. Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol. 1994;45(4):673-83. (Pubitemid 24139194)
76. Sadeghi R, Depledge P, Rawlins P, Dhanjal N, Manic A, Wrigley S, Foxwell B, Moore M. Differential regulation of CD3- and CD28-induced IL-2 and IFN-gamma production by a novel tyrosine kinase inhibitor XR774 from Cladosporium cf. cladosporioides. Int Immunopharmacol. 2001;1(1):33-48. (Pubitemid 32193600)
77. Finzi L, Shao MX, Paye F, Housset C, Nadel JA. Lipopolysaccharide initiates a positive feedback of epidermal growth factor receptor signaling by prostaglandin E2 in human biliary carcinoma cells. J Immunol. 2009;182(4):2269-76.